HIF-1α与BMSCs治疗SCII的研究现状与展望  

The Present Situation and Expectation on HIF-1α and Bone Marrow Mesenchymal Stem Cells in Therapy Spinal Cord Ischemia Reperfusion Injury

作　　者：田丽颖[1] 张振[1] 王君[1] 张玉明[1] 蔡承魁[1] 高昌俊[1] 张贵和[1] 孙绪德[1] 

机构地区：[1]第四军医大学唐都医院麻醉科,陕西西安710038

出　　处：《现代生物医学进展》2013年第1期173-176,共4页Progress in Modern Biomedicine

基　　金：全军"十一五"军队基金(2009专字第167号);2011年陕西省课题项目(2011k14-01-01)

摘　　要：脊髓缺血再灌注损伤(spinal cord ischemia reperfusion injury,SCII)是一种不可逆性脊髓损伤,其临床治疗效果差以及致残率高的特点给人们的工作和生活带来了巨大负担。因缺血而导致的局部组织低氧进而造成细胞受损是发生SCII的主要原因,低氧诱导因子-1α(hypoxia-inducible factor-1α,HIF-1α)在细胞的低氧应答过程中起到重要调控作用,其功能主要为增强缺氧细胞的代谢,从而对抗低氧对细胞的破坏。另外,采用干细胞移植技术治疗脊髓缺血再灌注损伤在动物实验中取得了可喜的效果,这给截瘫患者带来了康复的希望。骨髓间充质干细胞(bone mesenchymal stem cells,BMSCs)不仅具有多向分化潜能,还可接受外源性基因并稳定表达基因产物,且其表达具有组织特异性。因此,它在组织工程创伤修复、细胞替代治疗、基因治疗等方面具有很好的临床应用价值和广阔的应用前景。因此,HIF-1α联合BMSCs治疗SCII,有望取得更好的治疗效果。Spinal cord ischemia reperfusion injury is an irreversible damage to people and patients who suffer from this disease often lead to paraplegia at last. Therefore, it always causes a giant burden for the whole family. Hypoxia plays an important role in the mechanism of spinal cord ischemia reperfusion injury, and hypoxia-inducible factor-1α can induce cell metabolism in hypoxia. More- over, the development of stem cell transplantation technology has brought hope to people who suffer from paraplegia. Bone marrow mes- enchymal stem cells not only have the multiplex differentiation potential, but also can be transplanted by exogenous genes and expressed stability, and expression with histologic specificity. So, it is expected to get better effects on therapy spinal cord injury by using both HIF-1α and bone marrow mesenchymal stem cells.

关 键 词：低氧诱导因子-1Α 骨髓间充质干细胞 脊髓缺血再灌注损伤 

分 类 号：R651.2[医药卫生—外科学] R744[医药卫生—临床医学]